Cannabics Pharmaceuticals Inc (OTCQB: CNBX), a company involved in personalised cannabinoid based cancer medicine, announced yesterday that it has named Itamar Borochov as its new director and member of its board.
Borochov is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. He was the original founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and co-founder, said, 'The entire team is pleased to have Itamar return to the board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases.'
Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor
Blue Cell Therapeutics appoints Olav Hellebo as board chairman
enGene completes target enrollment for LEGEND pivotal cohort
IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025
Karyopharm Therapeutics awards inducement grants to new employees
RaySearch introduces RayIntelligence v2025 to enhance oncology analytics
ImmuPharma files patent for P140 'Immunormalizer' with precision diagnostic for autoimmune diseases
Avacta completes sale of Coris Bioconcept to 3B BlackBio Dx
YD Bio closes business combination and listing on Nasdaq Global Market
BeOne Medicines reports positive topline data for sonrotoclax in mantle cell lymphoma
NeoGenomics wins court ruling invalidating Natera patent claims